MedKoo Biosciences/Tenofovir alafenamide fumarate (1:1 salt)/314271/20g-免疫在线蚂蚁淘旗下平台

商品详细MedKoo Biosciences/Tenofovir alafenamide fumarate (1:1 salt)/314271/20g

MedKoo Biosciences/Tenofovir alafenamide fumarate (1:1 salt)/314271/20g

商品编号： 314271-20g

品牌： MedKoo

市场价： ¥137000.00

美元价： 82200.00

产地：美国(厂家直采)

公司：

产品分类：其他试剂

公司分类： Other_reagents

联系Q Q： 3392242852

电话号码： 4000-520-616

电子邮箱： info@ebiomall.com

立即询价

商品介绍

Tenofovir alafenamide, also known as TAF and GS-7340, is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of tenofovir. By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP). Tenofovir alafenamide fumarate was approved in November 2015 for treatment of HIV-1.

MedKoo Cat#: 314271
Name: Tenofovir alafenamide fumarate (1:1 salt)
CAS#: 379270-38-9 (fumarate)
Chemical Formula: C25H33N6O9P
Exact Mass:
Molecular Weight: 593.55
Elemental Analysis: C, 50.68; H, 5.61; N, 14.18; O, 24.30; P, 5.23

Related CAS #: 379270-38-9 (fumarate) 1392275-56-7 (hemifumarate) 379270-37-8 (free base)

Synonym: TAF; GS734; GS-734; GS 7340; Tenofovir alafenamide fumarate; trade name: Genvoya.

IUPAC/Chemical Name: (S)-isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate fumarate

InChi Key: MEJAFWXKUKMUIR-WIUYAKJJSA-N

InChi Code: InChI=1S/C21H29N6O5P.C4H4O4/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;2-1+/t15-,16+,33?;/m1./s1

SMILES Code: C[C@@H](C(OC(C)C)=O)N[P@@](OC1=CC=CC=C1)(CO[C@@H](CN2C=NC3=C(N=CN=C23)N)C)=O.O=C(/C=C/C(O)=O)O

Technical Data

Appearance:

White to off-white solid powder

Purity:

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

View CoA: current batch, Lot#BBC70118
View CoA: previous batch, Lot#TZC51228

QC Data:

View QC data: previous batch, Lot#TZC51228
NMR comparison of Tenofovir alafenamide derivatives: free base; hemifumarate salt and fumarate salt
View QC data: current batch, Lot#BBC70118

Safety Data Sheet (MSDS):

View Material Safety Data Sheet (MSDS)

Shipping Condition:

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:

Soluble in DMSO.

Shelf Life:

>2 years if stored properly

Drug Formulation:

This drug may be formulated in DMSO

Stock Solution Storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

293490

Additional Information

Related CAS#
CAS#379270-38-9 =Tenofovir alafenamide fumarate, 1:1
CAS#1392275-56-7= Tenofovir alafenamide hemifumarate, 2:1
CAS#379270-37-8 = Tenofovir alafenamide

References

1: Majewska A, Mlynarczyk-Bonikowska B, Malejczyk M, Mlynarczyk G, Majewski S. Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV. Mini Rev Med Chem. 2015;15(2):93-103. PubMed PMID: 25751258.

2: Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8. doi: 10.1097/QAI.0000000000000225. PubMed PMID: 24872136.

3: Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014 May;69(5):1362-9. doi: 10.1093/jac/dkt532. Epub 2014 Feb 6. PubMed PMID: 24508897.

4: Flexner C, Saag M. The antiretroviral drug pipeline: prospects and implications for future treatment research. Curr Opin HIV AIDS. 2013 Nov;8(6):572-8. doi: 10.1097/COH.0000000000000011. Review. PubMed PMID: 24100879.

5: De Clercq E. Dancing with chemical formulae of antivirals: a personal account. Biochem Pharmacol. 2013 Sep 15;86(6):711-25. doi: 10.1016/j.bcp.2013.07.012. Epub 2013 Jul 19. Review. PubMed PMID: 23876344.

6: Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. doi: 10.1097/QAI.0b013e3182965d45. PubMed PMID: 23807155.

7: De Clercq E. A Cutting-Edge View on the Current State of Antiviral Drug Development. Med Res Rev. 2013 Mar 11. doi: 10.1002/med.21281. [Epub ahead of print] PubMed PMID: 23495004.

8: Saag MS. New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. Top Antivir Med. 2012 Dec;20(5):162-7. Review. PubMed PMID: 23363694.

9: Permpalung N, Putcharoen O, Avihingsanon A, Ruxrungtham K. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012 Nov;13(16):2301-17. doi: 10.1517/14656566.2012.729040. Epub 2012 Oct 8. Review. PubMed PMID: 23043453.

10: Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012 Oct;56(10):5409-13. doi: 10.1128/AAC.01089-12. Epub 2012 Jul 30. PubMed PMID: 22850510; PubMed Central PMCID: PMC3457391.

11: Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012 Jul-Sep;14(3):168-78. Review. PubMed PMID: 22833060.

12: Kersh EN, Luo W, Zheng Q, Adams DR, Hanson D, Youngpairoj AS, Cong ME, Butler K, Hendry RM, McNicholl JM, Heneine W, Garcia-Lerma JG. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis. 2012 Sep 1;206(5):770-9. doi: 10.1093/infdis/jis422. Epub 2012 Jun 27. PubMed PMID: 22740713; PubMed Central PMCID: PMC3491742.

13: Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66. doi: 10.1021/mp3002045. Epub 2012 Jul 12. PubMed PMID: 22738467.

14: Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008 Jul;74(1):92-100. doi: 10.1124/mol.108.045526. Epub 2008 Apr 22. PubMed PMID: 18430788.

15: Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2007 Feb;51(2):543-50. Epub 2006 Dec 4. PubMed PMID: 17145787; PubMed Central PMCID: PMC1797775.

16: Cihlar T. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Curr Opin HIV AIDS. 2006 Sep;1(5):373-9. doi: 10.1097/01.COH.0000239849.20828.09. PubMed PMID: 19372836.

17: Van Rompay KK, Kearney BP, Sexton JJ, ColÃ³n R, Lawson JR, Blackwood EJ, Lee WA, Bischofberger N, Marthas ML. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14. PubMed PMID: 16810108.

18: Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005 May;49(5):1898-906. PubMed PMID: 15855512; PubMed Central PMCID: PMC1087627.

19: Chapman H, Kernan M, Prisbe E, Rohloff J, Sparacino M, Terhorst T, Yu R. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):621-8. PubMed PMID: 11563079.

20: Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1091-8. PubMed PMID: 11562963.

品牌介绍

MedKoo 美帝药库公司以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。。美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。美帝药库的药物化合物来源于以下几个渠道：自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成：（1）上市抗癌药库：该库将含有大约100个全球已批准上市的小分子抗癌化合物；（2）抗癌候选药物库：该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物；（3）同系抗癌分子库：该分子库将含有多个化学结构类似或抗癌机制类似的分子包；（4）抗癌分子预制模块库：该库主要含有用于组建抗癌目标分子的分子模块包；（5）同位素标记抗癌分子库。